| Symbol | SANA |
|---|---|
| Name | USANA HEALTH SCIENCES, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Medicinal Chemicals and Botanical Products |
| Address | 3838 WEST PARKWAY BOULEVARD, SALT LAKE CITY, Utah, 84120, United States |
| Telephone | +1 801 - 954-7100 |
| Fax | — |
| — | |
| Website | https://www.usana.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001770121 |
| Description | Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe, with the majority of its revenue generated from markets outside the United States. Additional info from NASDAQ: Additional info from NASDAQ: |
Bishop Hans Edgar 🟢 acquired 6.3K shares of Sana Biotechnology, Inc. (SANA) Transaction Date: Jul 06, 2026 | Filing ID: 000008
Read moreSana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
Read moreYang Patrick Y 🟢 acquired 90.0K shares (1 derivative) of Sana Biotechnology, Inc. (SANA) at $2.96 Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read moreSeitz Michelle 🟢 acquired 90.0K shares (1 derivative) of Sana Biotechnology, Inc. (SANA) at $2.96 Transaction Date: Jun 04, 2026 | Filing ID: 000014
Read moreREICIN ALISE 🟢 acquired 90.0K shares (1 derivative) of Sana Biotechnology, Inc. (SANA) at $2.96 Transaction Date: Jun 04, 2026 | Filing ID: 000011
Read moreBishop Hans Edgar 🟢 acquired 90.0K shares (1 derivative) of Sana Biotechnology, Inc. (SANA) at $2.96 Transaction Date: Jun 04, 2026 | Filing ID: 000006
Read moreBilenker Joshua H. 🟢 acquired 90.0K shares (1 derivative) of Sana Biotechnology, Inc. (SANA) at $2.96 Transaction Date: Jun 04, 2026 | Filing ID: 000002
Read moreDirector NELSEN ROBERT 🟢 acquired 90.0K shares (1 derivative) of Sana Biotechnology, Inc. (SANA) at $2.96 Transaction Date: Jun 04, 2026 | Filing ID: 000003
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06442293 | Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain … | Na | Safety Issues | Not_Yet_Recruiting | 2024-07-01 | 2024-08-15 | ClinicalTrials.gov |
| NCT05917015 | A Clinical Study to Determine if Beta Glucan Reduces the Incidence, Duration or… | Na | Upper Respiratory Tract Infections | Unknown | 2023-03-06 | 2023-12-31 | ClinicalTrials.gov |
| NCT06249698 | Active Nutrition Program on Weight Loss | Na | Weight Loss | Completed | 2022-02-22 | 2023-09-07 | ClinicalTrials.gov |
| NCT05443269 | Impact of Jump Start Nutrition Program on Weight Loss and Associated Measures | Na | Weight Loss | Unknown | 2022-02-14 | 2022-09-30 | ClinicalTrials.gov |
| NCT05330793 | The Effects of an Oral Probiotic Intervention With or Without a Novel ADP-1 Too… | Na | Oral Health | Completed | 2021-10-26 | 2022-12-16 | ClinicalTrials.gov |
| NCT05926050 | The Acute Effects of a Dietary Supplement on Cognitive Performance in Highly Tr… | Na | Reaction Time | Completed | 2021-09-08 | 2022-08-10 | ClinicalTrials.gov |
| NCT03782974 | A Follow-up Trial of Proglucamune® in the Treatment of Protective Qi Deficiency… | Na | Protective Qi Insufficiency (a Condition Term From TCM) | Completed | 2019-01-06 | 2019-06-06 | ClinicalTrials.gov |
| NCT03829228 | An Evaluation of Proglucamune in the Treatment of Protective Qi Insufficiency | Na | Protective Qi Insufficiency | Completed | 2018-03-18 | 2018-06-03 | ClinicalTrials.gov |
| NCT03146312 | Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indic… | Na | Healthy | Completed | 2017-04-20 | 2017-06-08 | ClinicalTrials.gov |
| NCT03488992 | Effect of a MVM Dietary Supplement on Indices of Human Health | Na | Metabolic Syndrome | Completed | 2017-01-10 | 2018-02-25 | ClinicalTrials.gov |
| NCT01488656 | Effects of Dietary Supplements on Response to Air Pollution | Na | Inflammation | Completed | 2011-11-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT04121533 | Vitamin D Supplementation in Knee Osteoarthritis | Na | Osteoarthritis, Knee | Completed | 2011-07-28 | 2013-01-08 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Antioxidant, anti-inflammatory dietary supplement | Other | Approved | Inflammation | COMPLETED | NCT01488656 |
| Placebo | Other | Approved | Inflammation | COMPLETED | NCT01488656 |
| Antioxidant, anti-inflammatory dietary supplement | Other | Approved | Inflammation | COMPLETED | NCT01488656 |
| Placebo | Other | Approved | Inflammation | COMPLETED | NCT01488656 |
| Placebo | Other | Approved | Healthy | COMPLETED | NCT03146312 |
| MVM/phytochemical supplement | Other | Approved | Healthy | COMPLETED | NCT03146312 |
| Placebo | Other | Approved | Healthy | COMPLETED | NCT03146312 |
| MVM/phytochemical supplement | Other | Approved | Healthy | COMPLETED | NCT03146312 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03488992 |
| MVM/phytochemical supplement | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03488992 |
| Placebo | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03488992 |
| MVM/phytochemical supplement | Other | Approved | Metabolic Syndrome | COMPLETED | NCT03488992 |
| Glucosamine sulfate and omega-3 fatty acids | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT04121533 |
| Vitamin D (cholecalciferol) | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT04121533 |
| Placebo | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT04121533 |
| Glucosamine sulfate and omega-3 fatty acids | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT04121533 |
| Vitamin D (cholecalciferol) | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT04121533 |
| Placebo | Other | Approved | Osteoarthritis, Knee | COMPLETED | NCT04121533 |
| Proglucamune | Other | Approved | Protective Qi Insufficiency | COMPLETED | NCT03829228 |
| Proglucamune | Other | Approved | Protective Qi Insufficiency | COMPLETED | NCT03829228 |
| Jump Start Nutritional Program | Other | Approved | Weight Loss | UNKNOWN | NCT05443269 |
| Jump Start Nutritional Program | Other | Approved | Weight Loss | UNKNOWN | NCT05443269 |
| Jump Start Nutritional Program | Other | Approved | Weight Loss | UNKNOWN | NCT05443269 |
| Placebo | Other | Approved | Oral Health | COMPLETED | NCT05330793 |
| Oral probiotic | Other | Approved | Oral Health | COMPLETED | NCT05330793 |
| Placebo | Other | Approved | Oral Health | COMPLETED | NCT05330793 |
| Oral probiotic | Other | Approved | Oral Health | COMPLETED | NCT05330793 |
| Placebo | Other | Approved | Upper Respiratory Tract Infections | UNKNOWN | NCT05917015 |
| Treatment | Drug | Approved | Upper Respiratory Tract Infections | UNKNOWN | NCT05917015 |
| Placebo | Other | Approved | Upper Respiratory Tract Infections | UNKNOWN | NCT05917015 |
| Treatment | Drug | Approved | Upper Respiratory Tract Infections | UNKNOWN | NCT05917015 |
| Placebo | Other | Approved | Reaction Time | COMPLETED | NCT05926050 |
| Treatment (CopaPrime+ (USANA Health Sciences) | Drug | Approved | Reaction Time | COMPLETED | NCT05926050 |
| Placebo | Other | Approved | Reaction Time | COMPLETED | NCT05926050 |
| Treatment (CopaPrime+ (USANA Health Sciences) | Drug | Approved | Reaction Time | COMPLETED | NCT05926050 |
| beta glucan | Other | Approved | Protective Qi Insufficiency (a Condition Term From TCM) | COMPLETED | NCT03782974 |
| beta glucan | Other | Approved | Protective Qi Insufficiency (a Condition Term From TCM) | COMPLETED | NCT03782974 |
| meal replacements and supplements | Other | Approved | Weight Loss | COMPLETED | NCT06249698 |
| meal replacements and supplements | Other | Approved | Weight Loss | COMPLETED | NCT06249698 |
| Placebo | Other | Approved | Safety Issues | NOT_YET_RECRUITING | NCT06442293 |
| Treatment 2 | Drug | Approved | Safety Issues | NOT_YET_RECRUITING | NCT06442293 |
| Treatment 1 | Drug | Approved | Safety Issues | NOT_YET_RECRUITING | NCT06442293 |
| Placebo | Other | Approved | Safety Issues | NOT_YET_RECRUITING | NCT06442293 |
| Treatment 2 | Drug | Approved | Safety Issues | NOT_YET_RECRUITING | NCT06442293 |
| Treatment 1 | Drug | Approved | Safety Issues | NOT_YET_RECRUITING | NCT06442293 |